|题名: ||Risperidone-Related Weight Gain: Genetic and Nongenetic Predictors|
|作者: ||Lane, Hsien-yuan;Liu, Yi-ching;Huang, Chieh-liang;張玉坤;Chang, Yue-cune;Wu, Po-lun;Lu, Chung-ta;Chang, Wen-ho|
|上传时间: ||2010-01-28 07:10:11 (UTC+8)|
|出版者: ||Lippincott, Williams & Wilkins|
|摘要: ||Objective: A serious side effect of atypical antipsychotics is increased body weight, which leads to further morbidity and nonadherence to medication. It has been suggested that both genetic and nongenetic variables may influence antipsychotics-related weight gain. This study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent.
Methods: One hundred twenty-three ethnically Han Chinese inpatients with acutely exacerbated schizophrenia were given risperidone monotherapy for up to 42 days. Body weight and clinical manifestations were assessed biweekly. Drug efficacy was measured by the Positive and Negative Syndrome Scale (PANSS), and safety was evaluated by the Extrapyramidal Symptom Rating Scale (ESRS) and the UKU Side Effect Rating Scale. We collected body weight as the response value. Potential prognostic factors were baseline body weight, age, sex, diagnosis subtypes, risperidone dosage, PANSS total scores, treatment duration (weeks 0-6), and 15 genetic variants [across 10 candidate genes: 5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, D1, D2, D3, and α1-adrenergic receptors, brain-derived neurotrophic factor (BDNF), and cytochrome P450 2D6 (CYP2D6)]. Because there were repeated assessments, multiple linear regression with the generalized estimating equation (GEE) method was used to adjust the within-subject dependence.
Results: Of 15 genetic polymorphisms examined, 5-HT2A 102-T/C, 5-HT2C −759-C/T, 5-HT6 267-C/T, BDNF 66-Val/Met, and CYP2D6 188-C/T significantly influenced body weight, and so did baseline body weight, age, gender, schizophrenia subtype, and treatment duration and efficacy.
|關聯: ||Journal of Clinical Psychopharmacology 26(2), pp.128-134|